Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.

Cyclin-dependent kinases (cdk) control the cell division cycle (cdc). These kinases and their regulators are frequently deregulated in human tumours. A potent inhibitor of cdks, roscovitine [2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurin e], was identified by screening a series of C2,N6,N9-substituted adenines on purified cdc2/cyclin B. Roscovitine displays high efficiency and high selectivity (Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J.-G. & Moulinoux, J.-P. (1997) Eur. J. Biochem. 243, 527-536). It behaves as a competitive inhibitor for ATP binding to cdc2. We determined the crystal structure of a complex between cdk2 and roscovitine at 0.24-nm (2.4 A) resolution and refined to an Rfactor of 0.18. The purine portion of the inhibitor binds to the adenine binding pocket of cdk2. The position of the benzyl ring group of the inhibitor enables the inhibitor to make contacts with the enzyme not observed in the ATP-complex structure. Analysis of the position of this benzyl ring explains the specificity of roscovitine in inhibiting cdk2. The structure also reveals that the (R)-stereoisomer of roscovitine is bound to cdk2. The (R)-isomer is about twice as potent in inhibiting cdc2/cyclin B than the (S)-isomer. Results from structure/activity studies and from analysis of the cdk2/roscovitine complex crystal structure should allow the design of even more potent cdk inhibitors.

[1]  X. Graña,et al.  Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). , 1995, Oncogene.

[2]  L Meijer,et al.  Multiple modes of ligand recognition: Crystal structures of cyclin‐dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine , 1995, Proteins.

[3]  R. A. Swank,et al.  Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. , 1992, Biochemical and biophysical research communications.

[4]  P. Russell,et al.  Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe. , 1990, Genes & development.

[5]  A. Harris,et al.  Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. , 1995, Journal of cell science.

[6]  P. Guerrier,et al.  6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity. , 1988, Experimental cell research.

[7]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[8]  A T Brünger,et al.  Slow-cooling protocols for crystallographic refinement by simulated annealing. , 1990, Acta crystallographica. Section A, Foundations of crystallography.

[9]  E. Sausville,et al.  Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. , 1993, Biochemical pharmacology.

[10]  Sung-Hou Kim,et al.  Sparse matrix sampling: a screening method for crystallization of proteins , 1991 .

[11]  A. Murray,et al.  The Cell Cycle: An Introduction , 1993 .

[12]  L Meijer,et al.  Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. , 1997, European journal of biochemistry.

[13]  S H Kim,et al.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. Meijer,et al.  Cyclic activation of histone H1 kinase during sea urchin egg mitotic divisions. , 1988, Experimental cell research.

[15]  N. Saijo,et al.  Effect of suramin on p34cdc2 kinase in vitro and in extracts from human H69 cells: evidence for a double mechanism of action. , 1994, Biochemical and biophysical research communications.

[16]  S. Kim,et al.  Purification and crystallization of human cyclin-dependent kinase 2. , 1993, Journal of molecular biology.

[17]  Jean,et al.  Cyclin B targets p34cdc2 for tyrosine phosphorylation. , 1991, The EMBO journal.

[18]  E. Nabel,et al.  The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo , 1995, Nature Medicine.

[19]  L. Meijer,et al.  Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions , 1994, FEBS letters.

[20]  C. Cordon-Cardo.  Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. , 1995, The American journal of pathology.

[21]  J. L. Smith,et al.  Structure of myohemerythrin in the azidomet state at 1.7/1.3 A resolution. , 1987, Journal of molecular biology.

[22]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[23]  L. Rebhun,et al.  Cleavage inhibition in marine eggs by puromycin and 6-dimethylaminopurine. , 1973, Experimental cell research.

[24]  C. Chothia,et al.  The structure of protein-protein recognition sites. , 1990, The Journal of biological chemistry.

[25]  C. W. Parker,et al.  Inhibitors of two enzymes which metabolize cytokinins , 1986 .

[26]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[27]  E. Schierenberg,et al.  Cellular effects of olomoucine, an inhibitor of cyclin‐dependent kinases , 1995, Biology of the cell.

[28]  V. Rialet,et al.  A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates. , 1991, Anticancer research.

[29]  S. Broder,et al.  Molecular foundations of cancer: New targets for intervention , 1995, Nature Medicine.

[30]  L. Meijer,et al.  A starfish oocyte user's guide , 1984 .

[31]  I. Wilson,et al.  Antibody-antigen interactions , 1993 .

[32]  E. Sausville,et al.  Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. , 1992, Journal of the National Cancer Institute.

[33]  E. Sausville,et al.  Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. , 1994, Biochemical and biophysical research communications.

[34]  M. L. Connolly.  Analytical molecular surface calculation , 1983 .

[35]  M. Kitagawa,et al.  Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. , 1993, Oncogene.

[36]  L. Meijer,et al.  Screening for antimitotic compounds using the cdc25 tyrosine phosphatase, an activator of the mitosis-inducing p34cdc2/cyclin Bcdc13 protein kinase. , 1992, Anticancer research.

[37]  S. Elledge,et al.  A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. , 1996, Trends in cell biology.

[38]  J. Thornton,et al.  Satisfying hydrogen bonding potential in proteins. , 1994, Journal of molecular biology.

[39]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[40]  J. H. Wang,et al.  Purification of a 15-kDa cdk4- and cdk5-binding protein. , 1994, The Journal of biological chemistry.

[41]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[42]  A. Okuyama,et al.  Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts. , 1994, Biochemical and biophysical research communications.

[43]  M. Kitagawa,et al.  A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. , 1994, Oncogene.

[44]  J. Pines,et al.  Cyclins and cyclin-dependent kinases: a biochemical view. , 1995, The Biochemical journal.

[45]  David O. Morgan,et al.  Principles of CDK regulation , 1995, Nature.

[46]  L. Meijer.  Chemical inhibitors of cyclin-dependent kinases. , 1996, Trends in cell biology.

[47]  H. Tung,et al.  Progress in Cell Cycle Research , 1999, Progress in Cell Cycle Research.

[48]  F. Chang.  The cell cycle: A practical approach , 1995 .

[49]  H. Tung,et al.  Interaction between the cell-cycle-control proteins p34cdc2 and p9CKShs2. Evidence for two cooperative binding domains in p9CKShs2. , 1992, European journal of biochemistry.